Matthew C.  Hill net worth and biography

Matthew Hill Biography and Net Worth

Matthew C. Hill holds the position of Chief Financial & Accounting Officer for PDS Biotechnology Corp. Mr. Hill is also Member of The American Institute of Certified Public Accountants.

In his past career Mr. Hill held the position of Chief Financial Officer of STRATA Skin Sciences, Inc., CFO & Investor Relations Contact at Velcera LLC, Chief Financial Officer at SS White Dental, Inc. and Chief Financial Officer & Secretary for EP MedSystems, Inc.

He received an undergraduate degree from Lehigh University.

What is Matthew C. Hill's net worth?

The estimated net worth of Matthew C. Hill is at least $9,900.00 as of December 12th, 2023. Mr. Hill owns 2,500 shares of PDS Biotechnology stock worth more than $9,900 as of March 29th. This net worth approximation does not reflect any other investments that Mr. Hill may own. Learn More about Matthew C. Hill's net worth.

How do I contact Matthew C. Hill?

The corporate mailing address for Mr. Hill and other PDS Biotechnology executives is 25B Vreeland Road, Florham Park NJ, 07932. PDS Biotechnology can also be reached via phone at (800) 208-3343 and via email at [email protected]. Learn More on Matthew C. Hill's contact information.

Has Matthew C. Hill been buying or selling shares of PDS Biotechnology?

Matthew C. Hill has not been actively trading shares of PDS Biotechnology over the course of the past ninety days. Most recently, on Monday, December 13th, Matthew C. Hill bought 2,900 shares of PDS Biotechnology stock. The stock was acquired at an average cost of $8.99 per share, with a total value of $26,071.00. Learn More on Matthew C. Hill's trading history.

Who are PDS Biotechnology's active insiders?

PDS Biotechnology's insider roster includes Steve Glover (Director), Matthew Hill (CFO), and Seth Van Voorhees (CFO). Learn More on PDS Biotechnology's active insiders.

Matthew C. Hill Insider Trading History at PDS Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2021Buy2,900$8.99$26,071.00View SEC Filing Icon  
See Full Table

Matthew C. Hill Buying and Selling Activity at PDS Biotechnology

This chart shows Matthew C Hill's buying and selling at PDS Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PDS Biotechnology Company Overview

PDS Biotechnology logo
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Read More

Today's Range

Now: $3.96
Low: $3.90
High: $4.56

50 Day Range

MA: $5.26
Low: $3.85
High: $6.59

2 Week Range

Now: $3.96
Low: $3.61
High: $10.27

Volume

2,283,905 shs

Average Volume

1,258,070 shs

Market Capitalization

$123.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72